Edaravone CAS 89-25-8; 1-Pheny-3-Methyl-5-Pyrazolone (PMP) High Purity

Short Description:

Name: Edaravone; 1-Pheny-3-Methyl-5-Pyrazolone (PMP) 

CAS: 89-25-8

Appearance: Light Yellow Crystal or Powder

Purity: ≥98.0% 

Edaravone is a potent new free radical scavenger used for the therapy of patients with acute brain infarction.

High Quality, Commercial Production 

Inquiry: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Supply with High Purity and Stable Quality
Name: Edaravone  
CAS: 89-25-8  

Chemical Properties:

Name Edaravone
Synonyms 1-Pheny-3-Methyl-5-Pyrazolone (PMP); MCI-186
CAS Number 89-25-8
CAT Number RF-PI237
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C10H10N2O
Molecular Weight 174.2
Density 1.12 g/cm3
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance Light Yellow Crystal or Powder
Purity ≥99.0% 
Melting Point 127.0~130.0℃
Loss on Drying ≤0.50%
Residue on Ignition ≤0.30%
Single Impurity ≤0.50%
Total Impurities ≤1.0%
Heavy Metals ≤20ppm
Solubility  Soluble in 5% Hydrochloric Acid
Test Standard Enterprise Standard
Usage API; Pharmaceutical Intermediates

Package & Storage:

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.

Advantages:

1

FAQ:

Application:

Edaravone (CAS 89-25-8) is a potent new free radical scavenger used for the therapy of patients with acute brain infarction. Edaravone is a radical scavenger and antioxidant which is able to protect against the effects of ischemia, probably by inhibiting the lipoxygenase system. Protects against MPTP-induced neurotoxicity. Inhibits autophagy. Edaravone was marketed in Japan for improving neurologic recovery following acute brain infarction. Currently, several agents classified as neuroprotectants and acting by diverse mechanisms (inhibition of glutamate release, blockade of calcium channels, lazaroids) have been marketed for treating the outcomes of brain damage due to trauma, ischemia or cardiac arrest. Edavarone is the first antioxidant with free radical scavenging activity to be introduced for this pathology.  

  • Write your message here and send it to us